Boston MA 宫颈癌临床试验
18项针对 宫颈癌的研究正在 Boston及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Distance-Based Exercise to Preserve Function and Prevent Disability
招募中
- Dana-Farber Cancer Institute, Boston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
招募中1 期
- Massachusetts General Hospital, Boston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
招募中2 期
- Dana-Farber Cancer Institute - Oncology Department, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
招募中1/2 期
- Tufts Medical Center, Boston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
招募中1 期
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
招募中1/2 期
- Massachusetts General Hospital, Boston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
招募中1 期
- Dana Farber Cancer Institute, Boston
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
招募中1 期
- Mass General Cancer Center, Boston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
招募中1 期
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
招募中1/2 期
- Massachusetts General Hospital Cancer Center, Boston
Personalized Risk-based Follow-up of Cervical Cancer Screening in Practice, RCT
招募中
- Massachusetts General Brigham, Boston
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
招募中1/2 期
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
招募中1 期
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- 以及另外 2 项
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
招募中1/2 期
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
招募中1/2 期
- Massachusetts General Hospital, Boston
Building Connections
招募中
- Disparities Research Unit, Massachusetts General Hospital, Boston
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
招募中2 期
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
招募中1/2 期
- Dana Farber Cancer Institute, Boston
其他城市的 宫颈癌试验
- Houston, TX34 项研究
- Nashville, TN19 项研究
- New York City, NY19 项研究
- Los Angeles, CA16 项研究
- Arlington, VA16 项研究
- San Antonio, TX14 项研究
- St. Louis, MO13 项研究
- Dallas, TX13 项研究
- Orlando, FL12 项研究
- Chicago, IL12 项研究
- Atlanta, GA11 项研究
- Columbus, OH11 项研究
Boston的其他研究
- 乳腺癌111 项研究
- 非小细胞肺癌90 项研究
- 癌症（所有类型）86 项研究
- 结直肠癌63 项研究
- 转移性癌症63 项研究
- 肺癌62 项研究
- 卵巢癌61 项研究
- 前列腺癌59 项研究
- 抑郁症52 项研究
- 子宫内膜癌50 项研究
- 心力衰竭44 项研究
- 急性髓系白血病44 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月5日。每项研究自行设定入选标准，由研究团队决定谁能参与。